Ethics and Publication Malpractice Policy

Ethics and Publication Malpractice Policy

The Journal of Drug Delivery and Biotherapeutics (JDDB) is committed to upholding the highest standards of publication ethics and follows the guidelines established by the Committee on Publication Ethics (COPE). This policy applies to all stakeholders in the publication process, including authors, reviewers, editors, and the publisher.

  1. Duties of Authors
  1. Originality and Plagiarism
    • Authors must ensure that their work is original and free of plagiarism. Proper citations must be provided for all referenced works.
    • Manuscripts found to contain plagiarized content will be rejected or retracted.
  2. Data Accuracy and Transparency
    • Authors must present accurate and reliable data. Fabrication, falsification, or selective reporting of data is unethical and unacceptable.
    • Authors are encouraged to provide access to raw data when requested and deposit data in publicly available repositories.
  3. Authorship Criteria
    • Authorship should be limited to individuals who have made significant contributions to the conception, design, execution, or interpretation of the study.
    • All co-authors must approve the final manuscript and agree to its submission.
  4. Conflict of Interest Disclosure
    • Authors must disclose any financial or personal conflicts of interest that could influence the research or its interpretation.
    • All funding sources must be acknowledged.
  5. Multiple Submissions
    • Submitting the same manuscript to more than one journal simultaneously is prohibited.
  1. Duties of Editors
  1. Editorial Independence
    • Editors have full authority over the editorial content of the journal and make decisions independently based on the manuscript’s academic merit, originality, and relevance to the journal's scope.
  2. Fair Play
    • Manuscripts are evaluated solely on their intellectual content, without regard to the authors' race, gender, sexual orientation, religious beliefs, ethnic origin, citizenship, or political philosophy.
  3. Confidentiality
    • Editors must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, and members of the editorial team.
  4. Conflict of Interest Management
    • Editors must recuse themselves from handling manuscripts in which they have conflicts of interest. Alternative editors will be assigned in such cases.
  5. Ethical Oversight
    • Editors are responsible for ensuring the journal follows ethical publishing practices and will address ethical concerns, including retractions and corrections, as per COPE guidelines.
  1. Duties of Reviewers
  1. Confidentiality
    • Manuscripts received for review must be treated as confidential documents and must not be shared or discussed outside the review process.
  2. Objectivity
    • Reviews must be conducted objectively, with constructive feedback provided. Personal criticism of authors is inappropriate.
  3. Timeliness
    • Reviewers are expected to provide their reviews promptly. If unable to meet the deadline, they should inform the editor immediately.
  4. Conflict of Interest Disclosure
    • Reviewers must disclose any conflicts of interest and recuse themselves from reviewing manuscripts where such conflicts exist.
  5. Acknowledgment of Sources
    • Reviewers should identify relevant published work that has not been cited by the authors and report any substantial similarities with other published work.
  1. Publisher’s Responsibilities
  1. Ethical Oversight
    • The publisher, Sennos Biotech, works with the editors to ensure adherence to ethical standards.
  2. Corrections and Retractions
    • The publisher will collaborate with editors to issue corrections, clarifications, retractions, or apologies when necessary.
  3. Support for Ethical Practices
    • The publisher provides training and resources to ensure that ethical guidelines are understood and followed by all stakeholders.
  1. Addressing Misconduct
  • Journal of Drug Delivery and Biotherapeutics (JDDB) takes allegations of research or publication misconduct seriously. Examples of misconduct include plagiarism, data fabrication, duplicate submission, and unethical research practices.
  • If misconduct is suspected:
    • The journal will investigate following COPE guidelines.
    • Authors may be asked to provide additional documentation or raw data.
    • Proven cases of misconduct may result in manuscript rejection, article retraction, or reporting to relevant authorities.
  1. Statement of Ethical Compliance
  • All research published in Journal of Drug Delivery and Biotherapeutics (JDDB) must comply with ethical standards such as:
    • The Declaration of Helsinki for studies involving humans.
    • Relevant guidelines for studies involving animals.
    • Institutional review board (IRB) or ethics committee approval.